DFP 13318

Drug Profile

DFP 13318

Alternative Names: DFP-13318; PEG-SN-38; PEG-SN-38 conjugates - Prolynx; PLX-0264; PLX-038; Polyethylene-glycol-SN 38-conjugates - ProLynx

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Prolynx
  • Developer Delta-Fly Pharma
  • Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Polyethylenes; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 30 May 2017 ProLynx receives patent allownace for cleavable linker technology on hydrogels in USA
  • 18 Mar 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02646852)
  • 11 Jan 2016 DFP 13318 is available for licensing as of 02 Jun 2015. http://www.prolynxllc.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top